The FDA on March 5, 2026, approved TECVAYLI® in combination with Daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a Proteasome Inhibitor and an Immunomodulatory agent. TECVAYLI® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
